Pedal (Foot/Leg) Edema in Leprosy — Notes

1. Why leprosy causes pedal edema — overview

2. Causes of pedal edema in leprosy

A. Leprosy (lepra) reactions — the most important cause

• A delayed-type hypersensitivity reaction from a sudden shift in cell-mediated immunity, seen mainly in borderline forms (BT, BB, BL).
• Pre-existing skin patches/plaques become acutely erythematous, swollen, and tender; edema of the extremities or face is frequent and can be dramatic enough to mimic erysipelas or angioedema.
• Associated with acute, painful nerve trunk swelling (neuritis) - "edema and mucosal/perineural swelling" from granuloma volume, inflammatory infiltrate, and intraneural/perineural edema compress the nerve and cause axonal damage (Goldman-Cecil Medicine).

• Occurs in lepromatous/borderline-lepromatous disease; an immune-complex-mediated (type III hypersensitivity) systemic vasculitis.
• Produces crops of tender erythematous nodules/plaques plus systemic symptoms: fever, malaise, and edema (of face, hands, and feet).
• Can be complicated by immune-complex glomerulonephritis, which adds a renal component to leg edema (proteinuria, salt/water retention).
• Extracutaneous involvement: neuritis, panniculitis, arthralgia/synovitis, epididymo-orchitis, iridocyclitis, osteitis, lymphadenitis (Fitzpatrick's Dermatology, Table 159-2).

• A severe, uncommon reaction seen mainly in diffuse lepromatous (Lucio) leprosy - bluish/violaceous hemorrhagic plaques evolving into large necrotic ulcers of the lower limbs, with a true necrotizing vasculitis; associated soft-tissue edema and can be life-threatening.

B. Nerve damage and its downstream effects

• M. leprae preferentially invades cooler, superficial nerve segments (ulnar, common peroneal, posterior tibial nerves at the ankle are classic sites), causing demyelination and axonal degeneration.
• Resulting motor weakness (foot drop, intrinsic foot muscle paralysis) impairs the calf/foot "muscle pump," reducing venous and lymphatic return and contributing to dependent edema.
• Autonomic nerve involvement causes loss of vasomotor tone, dry skin (xeroderma), and abnormal microvascular regulation, which also favors edema and poor tissue perfusion, predisposing to trophic changes.

C. Direct bacillary/granulomatous skin infiltration (lepromatous leprosy)

• Rheumatology and dermatology texts describe bilateral, symmetric edema of the hands and feet with cyanosis and xeroderma as a recognized musculoskeletal/cutaneous manifestation of lepromatous leprosy, independent of an acute reaction - due to diffuse dermal infiltration by M. leprae-laden macrophages (lepromas/hansenomas) that thickens and indurates the skin and subcutis, impairing normal drainage.

D. Secondary/complicating causes (often overlooked but important)

• Secondary bacterial cellulitis of insensate, ulcerated, or traumatized feet (very common because of loss of protective sensation and unnoticed injury).
• Chronic plantar ulcers with surrounding inflammation and lymphatic damage from repeated trauma/infection - a well-documented complication of leprosy neuropathy (recent systematic review/meta-analysis: plantar ulcer prevalence and risk factors in leprosy, PMID 37953361).
• Charcot (neuropathic) joints and osteoarticular destruction of the foot/ankle causing swelling.
• Secondary renal amyloidosis (AA amyloidosis) in long-standing multibacillary/lepromatous disease with recurrent ENL - leads to nephrotic syndrome and generalized (including pedal) edema from hypoalbuminemia.
• Drug-related edema/reactions:
  • Dapsone hypersensitivity syndrome (fever, edema, rash, hepatitis).
  • Clofazimine-induced skin changes.
  • Thalidomide is generally not a classic cause of edema but requires caution for other reasons (teratogenicity, neuropathy).
• Hypoalbuminemia from chronic illness/malnutrition in advanced disease.
• Lymphatic obstruction from chronic granulomatous lymphadenitis in lepromatous disease.

3. Management

A. General/supportive measures (apply to almost all causes)

• Rest and limb elevation - bed rest with the foot elevated above the level of the heart during acute reactional edema or neuritis; this is standard first-line advice in every leprosy reaction protocol.
• Do not stop MDT during a reaction - continue rifampicin, dapsone, clofazimine as scheduled unless a specific drug is implicated in a hypersensitivity reaction.
• Protective footwear and offloading for insensate feet to prevent trauma, ulceration, and secondary infection that worsen edema.
• Physiotherapy - passive and active exercises, splinting for foot drop, to maintain the muscle pump and joint mobility and to prevent contractures.
• Analgesics/NSAIDs for pain associated with neuritis or mild reactions.

B. Treating the specific reaction

• Silent/acute neuritis (nerve swelling/pain/function loss without necessarily overlying skin reaction) is treated the same way as reversal reaction - systemic corticosteroids started promptly, because the perineural/intraneural edema causing nerve compression is time-critical for preventing irreversible damage.

C. Managing complications and secondary causes

• Secondary cellulitis/infection: systemic antibiotics covering skin flora, wound care, and debridement of ulcers as needed.
• Chronic plantar ulcers: offloading (total contact casting or specialized footwear), regular wound care, treat any underlying osteomyelitis.
• Renal involvement (ENL-associated glomerulonephritis or amyloidosis): treat the underlying reaction, salt restriction, diuretics for symptomatic edema, nephrology referral, protein supplementation if hypoalbuminemic; renal biopsy if nephrotic-range proteinuria to distinguish immune-complex GN from amyloidosis, as management and prognosis differ.
• Charcot foot/osteoarticular damage: immobilization, orthotic support, surgical correction in advanced deformity.
• Drug reaction-related edema: stop/replace the offending drug (e.g., substitute for dapsone if hypersensitivity syndrome suspected), supportive care, corticosteroids if severe hypersensitivity.

D. Long-term prevention

• Routine self-care education (daily foot inspection, soaking, oiling, filing of calluses) to prevent unnoticed trauma leading to ulceration and secondary edema.
• Regular follow-up for nerve function assessment (voluntary muscle testing, sensory testing) to catch silent neuritis early.
• Periodic screening for renal function/proteinuria in patients with recurrent ENL or long-standing multibacillary disease.

Key teaching point

Revised & Complete Notes: Causes and Management of Pedal Edema in Leprosy

Complete List of Causes of Pedal Edema in Leprosy

1. Leprosy (lepra) reactions

• Type 1 / Reversal Reaction - acute worsening of existing lesions with edema of extremities/face; associated acute neuritis from perineural/intraneural edema.
• Type 2 Reaction / ENL - immune-complex vasculitis with fever, malaise, and edema of hands/feet; may progress to immune-complex glomerulonephritis.
• Lucio phenomenon - necrotizing vasculitis in diffuse lepromatous leprosy, with hemorrhagic infarct-like plaques, ulceration, and associated limb edema; leg ulcers secondary to venous insufficiency are specifically described in Lucio leprosy (Fitzpatrick's Dermatology).

2. Nerve damage and its consequences

• Motor nerve involvement (posterior tibial, common peroneal) -> foot drop and paralysis of intrinsic foot/calf muscles -> loss of the "muscle pump" -> dependent venous/lymphatic stasis edema.
• Autonomic nerve damage -> loss of vasomotor tone, dry skin, impaired microvascular regulation -> predisposes to edema and trophic change.
• Chronic neurotrophic (plantar) ulcers from insensate trauma -> local inflammatory edema.

3. Direct bacillary/granulomatous infiltration

• Diffuse dermal infiltration in lepromatous leprosy causes bilateral, symmetric edema of hands and feet with cyanosis and xeroderma, independent of an acute reaction (Rheumatology, 2-Vol Set).

4. Anemia (the cause you flagged - now added)

• Anemia of chronic disease/inflammation - from long-standing bacillary load and recurrent reactions (ENL), similar to any chronic granulomatous infection.
• Dapsone-induced hemolytic anemia - a well-documented adverse effect; "an insignificant degree of hemolysis occurs in virtually every patient" on dapsone but becomes clinically significant in G6PD-deficient patients (Goldman-Cecil Medicine). Chronic hemolysis contributes to a hyperdynamic/high-output circulatory state that can produce dependent edema, and cases of clinically significant dapsone-induced hemolytic anemia (even with normal G6PD) are reported in the literature.
• Dapsone-related bone marrow suppression (rarely aplastic anemia) and methemoglobinemia.
• Nutritional/malabsorptive anemia - from chronic illness, poor nutrition, and social deprivation associated with leprosy-related disability and stigma.
• Bone marrow infiltration in advanced multibacillary disease (rare).
• Severe chronic anemia -> reduced plasma oncotic support and, if marked, a high-output cardiac state with fluid retention, both of which favor dependent pedal edema, especially when compounded by hypoalbuminemia.
• Anemia is explicitly listed among the systemic "clinical constellation" findings of leprosy (alongside hypergammaglobulinemia and lupus-like serologic changes) in Fitzpatrick's Dermatology.

5. Renal causes

• ENL-associated immune-complex glomerulonephritis -> proteinuria, salt/water retention, edema.
• Secondary (AA) renal amyloidosis in long-standing multibacillary leprosy with recurrent ENL -> nephrotic syndrome, hypoalbuminemia, generalized edema.
• Leprosy is a recognized secondary cause of membranous nephropathy (National Kidney Foundation Primer on Kidney Diseases) -> nephrotic-range proteinuria and edema.

6. Hypoalbuminemia / protein deficiency

• From chronic infection/inflammation, poor nutrition, nephrotic-range proteinuria, or hepatic dysfunction (e.g., rifampicin/dapsone-related hepatitis reducing albumin synthesis).

7. Infective/secondary causes

• Secondary bacterial cellulitis of insensate or ulcerated feet.
• Chronic plantar ulcers with local lymphatic damage and recurrent low-grade infection.
• Lymphatic obstruction from chronic granulomatous lymphadenitis.

8. Musculoskeletal causes

• Neuropathic (Charcot) joints and osteoarticular destruction of foot/ankle.
• Septic arthritis or chronic reactive polyarthritis associated with lepra reactions.

9. Drug-related edema

• Dapsone hypersensitivity syndrome (fever, rash, edema, lymphadenopathy, hepatitis) - onset typically 4-6 weeks after starting dapsone.
• Clofazimine-related tissue/crystal deposition effects (less directly causes edema but contributes to systemic morbidity).
• Hepatotoxicity from rifampicin/dapsone reducing albumin synthesis.

10. Coincidental/non-leprosy causes to always rule out

• Venous insufficiency/immobility-related dependent edema (compounded by leprosy-related disability and reduced mobility).
• Cardiac, hepatic, thyroid, or renal comorbidity unrelated to leprosy itself, especially in older or multimorbid patients.
• Filariasis or other endemic co-infections in overlapping geographic regions.

Management (updated)

General measures

• Rest with limb elevation during acute reactional edema/neuritis.
• Continue MDT (rifampicin, dapsone, clofazimine) unless a specific drug is implicated in a hypersensitivity/hemolytic reaction.
• Protective footwear, offloading, physiotherapy, and splinting for neuropathic/motor deficits.

Reaction-specific treatment

• Type 1 (Reversal): Prednisolone 1-2 mg/kg/day, tapered slowly over ~3 months.
• Type 2 (ENL): Thalidomide 100-400 mg/day ± prednisolone, or clofazimine/pentoxifylline as alternatives; avoid thalidomide in women of childbearing potential.
• Silent/acute neuritis: Prompt systemic corticosteroids to prevent irreversible nerve damage; nerve decompression surgery if refractory.

Managing anemia specifically

• Investigate cause: CBC with reticulocyte count, peripheral smear, G6PD level, LFTs, direct/indirect Coombs if hemolysis suspected, iron/B12/folate studies for nutritional causes.
• If dapsone-induced hemolysis is significant: consider dose reduction, switching to an alternative regimen, or adding folic acid; monitor closely in G6PD-deficient patients.
• Correct nutritional deficiencies; transfuse only if severe/symptomatic anemia.
• Treat the underlying chronic inflammatory driver (i.e., control the leprosy reaction) since anemia of chronic disease improves as systemic inflammation is controlled.

Renal and protein-related causes

• Screen for proteinuria/renal function periodically, especially with recurrent ENL or long-standing multibacillary disease.
• Renal biopsy if nephrotic-range proteinuria to distinguish immune-complex GN from amyloidosis (different prognosis/management).
• Diuretics, salt restriction, and protein/nutritional support for symptomatic edema from hypoalbuminemia.

Secondary/infective causes

• Antibiotics and wound care for cellulitis or infected ulcers.
• Offloading and specialized footwear for chronic plantar ulcers.

Drug reactions

• Recognize and manage dapsone hypersensitivity syndrome promptly (stop dapsone, systemic corticosteroids in severe cases).
• Monitor hematologic parameters regularly in all patients on dapsone-containing MDT.